A deceptively simple analytical problem.
During cation‑exchange HPLC screening, falsely elevated Hb A₂ levels most often stem from co‑eluting hemoglobin variants — Hb E, Hb Lepore, Hb Osu‑Christiansborg, and Hb G‑Coushatta are prime examples — or post‑translationally modified hemoglobins such as carbamylated or glycated Hb S. These species share the same retention time as Hb A₂, producing a peak that is a composite signal rather than a pure A₂ measurement. Laboratories resolve this by extending high‑resolution analysis, applying mathematical baseline corrections, and, crucially, employing orthogonal confirmation methods like capillary electrophoresis or DNA analysis to distinguish true beta‑thalassemia trait from analytical interferences.
An Hb A₂ peak area greater than 10% in a cation‑exchange HPLC trace is a powerful red flag for co‑elution. Trusting that number without confirmation can lead to misdiagnosis and unnecessary genetic counseling. The core solution is a systematic, multi‑method reflex strategy that separates true elevation from analytical imposters.
Why Accurate Hb A₂ Matters More Than You Think
Hb A₂ (α₂δ₂) is the second‑most abundant adult hemoglobin, and its quantification is the cornerstone of beta‑thalassemia trait screening. A genuine elevation above 3.5–4.0% strongly suggests a reduction in beta‑globin chain synthesis.
When a spurious elevation enters the workflow, the consequences ripple outward. Patients may be wrongly labeled as carriers, triggering anxiety, partner testing, and invasive prenatal procedures. For the laboratory, it means wasted resources and a dent in credibility.
Therefore, understanding the causes of false elevation and how to neutralize them isn’t just an academic exercise — it’s a patient‑safety imperative.
The Culprits Behind Falsely Elevated Hb A₂
Cation‑exchange HPLC separates hemoglobin species based on their net surface charge. The method is robust, but it is not blind to molecules that carry a similar overall charge to Hb A₂.
Hemoglobin Variants That Mimic Hb A₂
The most notorious interferent is Hb E, a beta‑chain variant (β26 Glu→Lys) common in Southeast Asian populations. Because its charge is nearly identical to Hb A₂, it elutes in the same window, creating a single composite peak that can exceed 20–30%.
Hb Lepore, a δβ fusion variant, also co‑elutes in the A₂ window. Less common but equally problematic are Hb Osu‑Christiansborg and Hb G‑Coushatta, both beta‑chain mutants that shift the retention time right into the Hb A₂ zone.
In all these cases, the HPLC instrument faithfully reports the sum of Hb A₂ and the variant. You are not seeing a pure signal; you are seeing a crowd.
Post‑Translational Modifications in Samples With Hb S
Even in the absence of a typical variant, sample matrix can create an illusion. Patients with sickle cell disease or trait often have carbamylated or glycated Hb S adducts.
These chemically modified forms lose enough positive charge to migrate into the Hb A₂ region. The result is a modest but clinically confusing pseudo‑elevation, often in the 4–8% range, that can mimic borderline beta‑thalassemia trait.
How Laboratories Unmask the True Hb A₂ Value
A single HPLC run is not the final verdict. Smart laboratories build a layered defense that starts with subtle analytical adjustments and escalates to definitive technology.
Extended High‑Resolution Analysis Modes
Most modern HPLC analyzers offer an extended elution program. By flattening the gradient or lengthening the run time, you can partially resolve shoulder peaks that hint at co‑elution.
However, this approach is not foolproof. Hb E and Hb A₂ may still merge into a single nearly Gaussian peak, and an inexperienced eye will miss the slight asymmetry. Extended modes are a useful first screen, not a standalone solution.
Mathematical Baseline Corrections
Software can deconvolute overlapping peaks using advanced algorithms that model the expected peak shape. If the baseline between two components is ill‑defined, the system can apply a drop‑line integration or fit a curve to subtract the variant’s contribution.
This technique is elegant but dangerously blind. It assumes the interfering peak is symmetrical and that no other unknown species is present. In routine practice, it often underestimates the problem or introduces numerical artifacts, so it should never be the only confirmation step.
Orthogonal Confirmation With Capillary Electrophoresis
This is the workhorse of reflex testing. Capillary zone electrophoresis (CZE) separates hemoglobin species in free solution based on their electrophoretic mobility, which is governed by a different physical property than retention time.
Hb E and Hb A₂ are cleanly separated into two distinct, sharp zones on a CZE electropherogram. Other variants that co‑migrate on HPLC also often show unique positions. Running the same sample on CZE immediately reveals whether the original A₂ peak was pure or contaminated.
When to Escalate to DNA Analysis
If CZE still leaves ambiguity — for instance, a rare variant that co‑migrates in both methods — the definitive answer lies in molecular genetic testing. Sequencing the beta‑globin gene identifies the exact mutation and conclusively settles the question of beta‑thalassemia carrier status.
DNA analysis is the gold standard, but it is slower and more expensive. It should be reserved for cases where the biochemical picture remains unclear after orthogonal testing.
Understanding the Trade‑offs
No single approach is perfect. A robust strategy acknowledges the inherent friction between speed, cost, and diagnostic certainty.
- Extended HPLC runs increase turnaround time and may still leave doubt.
- Baseline correction software can mask a real variant, giving a false sense of security.
- Capillary electrophoresis requires a second instrument and consumables, adding cost and training.
- Molecular testing is resource‑intensive and not suitable for high‑throughput screening.
The risk of over‑relying on HPLC alone is particularly high in populations with a high prevalence of Hb E or sickle cell trait. A false‑negative on a partner’s thalassemia screen can have life‑altering consequences.
Building a Resilient Screening Strategy
Integrating these insights into a practical workflow is the final step. The right choice depends on your laboratory’s patient population, volume, and budget.
- If your primary focus is high‑volume population screening for beta‑thalassemia: Automate a reflex protocol that sends every sample with an Hb A₂ >10% on HPLC directly to capillary electrophoresis. This catches the majority of Hb E and other co‑eluting variants without overwhelming staff.
- If your primary focus is comprehensive variant identification: Pair HPLC with capillary electrophoresis on every sample. The combined chromatogram and electropherogram create a fingerprint that resolves most common and many rare hemoglobinopathies, reducing the need for DNA testing.
- If your primary focus is cost containment without sacrificing accuracy: Train technologists to visually inspect every HPLC chromatogram for peak asymmetry or unusual shoulders in the A₂ window. Only those with suspicious patterns or A₂ >10% are reflexed to CZE or basic molecular panels.
A single number on an HPLC report is never the whole story. When you treat it as a conversation starter — backed by a thoughtful, multi‑method safety net — you protect both the patient and the integrity of your screening program.
Summary Table:
| Cause / Interferent | Mechanism of Interference | Impact on HPLC | Resolution Strategy |
|---|---|---|---|
| Co-eluting Variants (Hb E, Hb Lepore, Hb G-Coushatta) |
Share charge & retention time with Hb A₂ | Composite peak; falsely high A₂ (>10%) | Orthogonal reflex testing via Capillary Zone Electrophoresis (CZE) |
| Post-Translational Adducts (Carbamylated / Glycated Hb S) |
Charge reduction shifts adducts into A₂ retention window | Pseudo-elevation (4–8%) mimicking beta-thal trait | Visual chromatogram inspection & CZE separation |
| Gradient & Integration Limits | Standard program fails to resolve subtle peak asymmetry | Misinterpretation of variant shoulder as pure A₂ | Extended high-resolution HPLC runs & deconvolution algorithms |
Enhance Your IVD Assay Performance with CamelBio
Eliminating analytical interferences and ensuring diagnostic precision requires robust assay design and dependable raw materials. CamelBio provides diagnostic manufacturers, clinical laboratories, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage of development from concept to clinic.
Whether you are refining hemoglobinopathy assays or developing next-generation diagnostic platforms, our team is here to support your technical and regulatory requirements. Contact CamelBio today to optimize your assay workflows!